A global biotechnology company focused on developing diagnoses for neurodegenerative disorders, Amprion, has secured $6 million in the initial close of its $15 million series B funding round.
According to the company’s announcement last week, the initial phase of the funding round was spearheaded by Formation Venture Engineering (FVE), with significant contributions from Eli Lilly and Company, alongside its Series A investors.
Co-founded in 2007 by Russell Lebovitz, Ph.D, and Claudio Soto, Ph.D, the company has developed early detection technology for Parkinson’s and Alzheimer’s, enabling scientists to discover and understand brain health better.
Amprion will use the Series B funding to expand its commercial footprint globally and boost R&D investment to achieve its mission of revolutionizing the detection of brain illnesses.
The funds will also help the company to accelerate the development of precision treatments for neurodegenerative disorders.
Revolutionizing Precision Medicine
Amprion has advanced neurodegenerative disorder detection technology allowing for early detection. It has evolved seed amplification testing, which allows even small amounts of misfolded protein to be detected in biological samples.
So far, the company’s SAAmplify-ɑSYN biomarker test is the only validated seed amplification assay designed for diagnosing synucleinopathies related to Alzheimer’s, Lewy body dementia, and Parkinson’s disease pathology.
The company has also collaborated with notable pharmaceutical companies to create effective medicines for Parkinson’s disease and other neurodegenerative illnesses.
Meanwhile, Amprion has already submitted an application to New York’s Department of Health, allowing it to expand its footprint in the United States.
